|
G |
Btn2a2 |
butyrophilin, subfamily 2, member A2 |
increases expression |
ISO |
Perfume results in increased expression of BTN2A2 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr17:41,620,807...41,632,621
Ensembl chr17:41,620,839...41,632,618
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
decreases expression |
ISO |
Perfume results in decreased expression of CADM1 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833
|
|
G |
Calu |
calumenin |
increases expression |
ISO |
Perfume results in increased expression of CALU mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
increases expression |
ISO |
Perfume results in increased expression of CCL13 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl17 |
C-C motif chemokine ligand 17 |
increases expression |
ISO |
Perfume results in increased expression of CCL17 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr19:10,202,128...10,203,903
Ensembl chr19:10,202,128...10,203,819
|
|
G |
Ccl19 |
C-C motif chemokine ligand 19 |
increases expression |
ISO |
Perfume results in increased expression of CCL19 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 5:56,963,364...56,965,308
Ensembl chr 5:56,963,364...56,965,308
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
ISO |
Perfume results in increased expression of CCL20 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
increases expression |
ISO |
Perfume results in increased expression of CCL21 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
increases expression |
ISO |
Perfume results in increased expression of CCL22 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
|
|
G |
Ccl26 |
C-C motif chemokine ligand 26 |
increases expression |
ISO |
Perfume results in increased expression of CCL26 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr12:21,109,384...21,114,336
Ensembl chr12:21,109,421...21,114,335
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
Perfume results in increased expression of CCL5 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
increases expression |
ISO |
Perfume results in increased expression of CCR7 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
ISO |
Perfume results in increased expression of CD68 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cfap300 |
cilia and flagella associated protein 300 |
increases expression |
ISO |
Perfume results in increased expression of CFAP300 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 8:5,180,180...5,198,840
Ensembl chr 8:5,180,675...5,198,807
|
|
G |
Cldn1 |
claudin 1 |
affects response to substance |
ISO |
CLDN1 gene SNP affects the susceptibility to Perfume |
CTD |
PMID:23136956 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Clec4g |
C-type lectin domain family 4, member G |
increases expression |
ISO |
Perfume results in increased expression of CLEC4G mRNA |
CTD |
PMID:24768652 |
|
NCBI chr12:1,780,370...1,785,027
Ensembl chr12:1,780,371...1,784,985
|
|
G |
Crlf2 |
cytokine receptor-like factor 2 |
increases expression |
ISO |
Perfume results in increased expression of CRLF2 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr14:103,943...108,643
Ensembl chr14:103,939...108,642
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
Perfume results in increased expression of CXCL10 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases expression |
ISO |
Perfume results in increased expression of CXCL11 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
increases expression |
ISO |
Perfume results in increased expression of CXCL9 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Dab2 |
DAB adaptor protein 2 |
increases expression |
ISO |
Perfume results in increased expression of DAB2 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476
|
|
G |
Dnase1l3 |
deoxyribonuclease 1L3 |
increases expression |
ISO |
Perfume results in increased expression of DNASE1L3 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr15:16,922,335...16,948,322
Ensembl chr15:16,922,335...16,948,317
|
|
G |
Elmo1 |
engulfment and cell motility 1 |
increases expression |
ISO |
Perfume results in increased expression of ELMO1 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr17:44,286,495...44,822,668
Ensembl chr17:44,286,485...44,822,788
|
|
G |
Fanci |
FA complementation group I |
increases expression |
ISO |
Perfume results in increased expression of FANCI mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 1:133,327,264...133,383,661
Ensembl chr 1:133,327,297...133,383,640
|
|
G |
Fcrla |
Fc receptor-like A |
increases expression |
ISO |
Perfume results in increased expression of FCRLA mRNA |
CTD |
PMID:24768652 |
|
NCBI chr13:83,160,453...83,170,170
Ensembl chr13:83,160,398...83,170,762
|
|
G |
Fgd2 |
FYVE, RhoGEF and PH domain containing 2 |
increases expression |
ISO |
Perfume results in increased expression of FGD2 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr20:7,424,795...7,441,603
Ensembl chr20:7,424,790...7,441,603
|
|
G |
Foxp3 |
forkhead box P3 |
increases expression |
ISO |
Perfume results in increased expression of FOXP3 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Fuca2 |
alpha-L-fucosidase 2 |
increases expression |
ISO |
Perfume results in increased expression of FUCA2 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 1:7,885,986...7,900,777
Ensembl chr 1:7,885,918...7,900,776
|
|
G |
Gata3 |
GATA binding protein 3 |
increases expression |
ISO |
Perfume results in increased expression of GATA3 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Glipr1 |
GLI pathogenesis-related 1 |
increases expression |
ISO |
Perfume results in increased expression of GLIPR1 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 7:47,487,342...47,498,974
Ensembl chr 7:47,487,345...47,498,429
|
|
G |
Ifna1 |
interferon, alpha 1 |
decreases expression |
ISO |
Perfume results in decreased expression of IFNA1 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:103,097,356...103,097,925
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
Perfume results in increased expression of IFNG mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbip |
IKBKB interacting protein |
increases expression |
ISO |
Perfume results in increased expression of IKBIP mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 7:25,579,865...25,598,548
Ensembl chr 7:25,579,832...25,605,162
|
|
G |
Il10 |
interleukin 10 |
increases expression |
ISO |
Perfume results in increased expression of IL10 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
Perfume results in increased expression of IL12B mRNA |
CTD |
PMID:24768652 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
increases expression |
ISO |
Perfume results in increased expression of IL13 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il17a |
interleukin 17A |
increases expression |
ISO |
Perfume results in increased expression of IL17A mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il17f |
interleukin 17F |
decreases expression |
ISO |
Perfume results in decreased expression of IL17F mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Perfume results in increased expression of IL1B mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
increases expression |
ISO |
Perfume results in increased expression of IL2 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il22 |
interleukin 22 |
increases expression |
ISO |
Perfume results in increased expression of IL22 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 7:53,801,206...53,805,673
Ensembl chr 7:53,801,206...53,806,186
|
|
G |
Il23a |
interleukin 23 subunit alpha |
increases expression |
ISO |
Perfume results in increased expression of IL23A mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
increases expression |
ISO |
Perfume results in increased expression of IL2RA mRNA |
CTD |
PMID:24768652 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il31 |
interleukin 31 |
increases expression |
ISO |
Perfume results in increased expression of IL31 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr12:33,095,108...33,105,026
Ensembl chr12:33,092,097...33,105,037
|
|
G |
Il33 |
interleukin 33 |
decreases expression |
ISO |
Perfume results in decreased expression of IL33 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Il4 |
interleukin 4 |
increases expression |
ISO |
Perfume results in increased expression of IL4 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
increases expression |
ISO |
Perfume results in increased expression of IL5 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
Perfume results in increased expression of IL6 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il7 |
interleukin 7 |
decreases expression |
ISO |
Perfume results in decreased expression of IL7 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 2:94,235,219...94,280,075
Ensembl chr 2:94,234,766...94,280,075
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
Perfume results in increased expression of IL7R mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757
|
|
G |
Il9 |
interleukin 9 |
increases expression |
ISO |
Perfume results in increased expression of IL9 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr17:8,111,772...8,114,895
Ensembl chr17:8,111,772...8,114,895
|
|
G |
Kdelr3 |
KDEL endoplasmic reticulum protein retention receptor 3 |
increases expression |
ISO |
Perfume results in increased expression of KDELR3 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 7:111,079,236...111,089,463
Ensembl chr 7:111,079,218...111,101,600
|
|
G |
Lcn2 |
lipocalin 2 |
decreases expression |
ISO |
Perfume results in decreased expression of LCN2 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Map7d3 |
MAP7 domain containing 3 |
increases expression |
ISO |
Perfume results in increased expression of MAP7D3 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr X:134,619,227...134,647,525
Ensembl chr X:134,619,227...134,685,841
|
|
G |
Masp1 |
MBL associated serine protease 1 |
increases expression |
ISO |
Perfume results in increased expression of MASP1 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr11:77,334,794...77,405,271
Ensembl chr11:77,334,859...77,402,974
|
|
G |
Mx1 |
MX dynamin like GTPase 1 |
increases expression |
ISO |
Perfume results in increased expression of MX1 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507
|
|
G |
Myo5a |
myosin VA |
increases expression |
ISO |
Perfume results in increased expression of MYO5A mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 8:75,811,985...75,980,049
Ensembl chr 8:75,812,412...75,975,918
|
|
G |
Nts |
neurotensin |
increases expression |
ISO |
Perfume results in increased expression of NTS mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Pdap1 |
PDGFA associated protein 1 |
increases expression |
ISO |
Perfume results in increased expression of PDAP1 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr12:9,470,652...9,480,880
Ensembl chr12:9,470,574...9,535,374
|
|
G |
Poc1a |
POC1 centriolar protein A |
increases expression |
ISO |
Perfume results in increased expression of POC1A mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 8:106,922,058...106,991,678
Ensembl chr 8:106,922,978...106,991,089
|
|
G |
Pole2 |
DNA polymerase epsilon 2, accessory subunit |
increases expression |
ISO |
Perfume results in increased expression of POLE2 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305
|
|
G |
Rab32 |
RAB32, member RAS oncogene family |
increases expression |
ISO |
Perfume results in increased expression of RAB32 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 1:4,946,193...4,961,003
Ensembl chr 1:4,945,036...4,960,934
|
|
G |
Rnase6 |
ribonuclease A family member 6 |
increases expression |
ISO |
Perfume results in increased expression of RNASE6 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr15:24,354,305...24,357,289
Ensembl chr15:24,354,303...24,357,328
|
|
G |
Rorc |
RAR-related orphan receptor C |
decreases expression |
ISO |
Perfume results in decreased expression of RORC mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
increases expression |
ISO |
Perfume results in increased expression of S100A8 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
Perfume results in increased expression of S100A9 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Sepsecs |
Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase |
increases expression |
ISO |
Perfume results in increased expression of SEPSECS mRNA |
CTD |
PMID:24768652 |
|
NCBI chr14:58,311,484...58,341,745
Ensembl chr14:58,311,499...58,341,740
|
|
G |
Sgo2 |
shugoshin 2 |
increases expression |
ISO |
Perfume results in increased expression of SGO2 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 9:59,548,605...59,573,229
Ensembl chr 9:59,548,683...59,573,229
|
|
G |
Slfn4 |
schlafen family member 4 |
increases expression |
ISO |
Perfume results in increased expression of SLFN1 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr10:67,994,601...68,018,141
Ensembl chr10:68,000,028...68,018,138 Ensembl chr10:68,000,028...68,018,138
|
|
G |
Spi1 |
Spi-1 proto-oncogene |
increases expression |
ISO |
Perfume results in increased expression of SPI1 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 3:77,059,744...77,093,730
Ensembl chr 3:77,073,012...77,092,393
|
|
G |
Ssuh2 |
ssu-2 homolog |
increases expression |
ISO |
Perfume results in increased expression of SSUH2 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 4:145,502,942...145,521,881
Ensembl chr 4:145,503,185...145,521,735
|
|
G |
Tbc1d31 |
TBC1 domain family, member 31 |
increases expression |
ISO |
Perfume results in increased expression of TBC1D31 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 7:89,427,354...89,506,894
Ensembl chr 7:89,426,780...89,506,894
|
|
G |
Tbx21 |
T-box transcription factor 21 |
increases expression |
ISO |
Perfume results in increased expression of TBX21 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr10:82,082,322...82,098,831
Ensembl chr10:82,082,322...82,098,831
|
|
G |
Tcp11l1 |
t-complex 11 like 1 |
increases expression |
ISO |
Perfume results in increased expression of TCP11L1 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 3:91,047,006...91,092,687
Ensembl chr 3:90,998,270...91,092,006
|
|
G |
Tdrkh |
tudor and KH domain containing |
increases expression |
ISO |
Perfume results in increased expression of TDRKH mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 2:182,049,175...182,071,516
Ensembl chr 2:182,049,215...182,070,755
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
Perfume results in increased expression of TGFB1 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tmeff2 |
transmembrane protein with EGF-like and two follistatin-like domains 2 |
increases expression |
ISO |
Perfume results in increased expression of TMEFF2 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 9:50,445,947...50,733,473
Ensembl chr 9:50,436,079...50,733,475
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
Perfume results in increased expression of TNF mRNA |
CTD |
PMID:24768652 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf4 |
TNF receptor superfamily member 4 |
increases expression |
ISO |
Perfume results in increased expression of TNFRSF4 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr 5:166,606,909...166,609,599
Ensembl chr 5:166,606,909...166,609,599
|
|
G |
Tnfsf4 |
TNF superfamily member 4 |
increases expression |
ISO |
Perfume results in increased expression of TNFSF4 mRNA |
CTD |
PMID:24768652 |
|
NCBI chr13:73,723,329...73,746,809
Ensembl chr13:73,723,329...73,746,788
|
|
G |
Vsir |
V-set immunoregulatory receptor |
increases expression |
ISO |
Perfume results in increased expression of VSIR mRNA |
CTD |
PMID:24768652 |
|
NCBI chr20:28,281,582...28,307,262
Ensembl chr20:28,281,596...28,303,878
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACACA mRNA |
CTD |
PMID:38000518 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ACACB mRNA |
CTD |
PMID:38000518 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acly |
ATP citrate lyase |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACLY mRNA |
CTD |
PMID:38000518 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of ACTA2 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AHR mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of AKT1 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
linalyl acetate inhibits the reaction [Testosterone results in increased activity of AR protein] |
CTD |
PMID:31393563 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of CAT mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CTGF mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of COL1A1 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT1A mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CPT2 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Ctsd |
cathepsin D |
increases expression multiple interactions |
ISO |
linalyl acetate results in increased expression of CTSD mRNA Fulvestrant inhibits the reaction [linalyl acetate results in increased expression of CTSD mRNA] |
CTD |
PMID:31393563 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of CYP1A1 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp4f6 |
cytochrome P450, family 4, subfamily f, polypeptide 6 |
multiple interactions |
ISO |
linalyl acetate inhibits the reaction [Testosterone results in increased expression of CYP4F8 mRNA] |
CTD |
PMID:31393563 |
|
NCBI chr 7:12,030,276...12,058,020
Ensembl chr 7:12,030,301...12,057,782
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of DGAT1 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Esr1 |
estrogen receptor 1 |
increases activity multiple interactions |
ISO |
linalyl acetate results in increased activity of ESR1 protein NCOA2 protein promotes the reaction [linalyl acetate results in increased activity of ESR1 protein] |
CTD |
PMID:31393563 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FASN mRNA |
CTD |
PMID:38000518 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of FOXO1 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GPX1 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Greb1 |
growth regulating estrogen receptor binding 1 |
increases expression multiple interactions |
ISO |
linalyl acetate results in increased expression of GREB1 mRNA Fulvestrant inhibits the reaction [linalyl acetate results in increased expression of GREB1 mRNA] |
CTD |
PMID:31393563 |
|
NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of GSR mRNA |
CTD |
PMID:38000518 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
linalyl acetate inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] |
CTD |
PMID:29276222 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Mlycd |
malonyl-CoA decarboxylase |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of MLYCD mRNA |
CTD |
PMID:38000518 |
|
NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
NCOA2 protein promotes the reaction [linalyl acetate results in increased activity of ESR1 protein] |
CTD |
PMID:31393563 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFE2L2 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of NFKB1 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Pgr |
progesterone receptor |
increases expression multiple interactions |
ISO |
linalyl acetate results in increased expression of PGR mRNA Fulvestrant inhibits the reaction [linalyl acetate results in increased expression of PGR mRNA] |
CTD |
PMID:31393563 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PPARA mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of PTGS1 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
linalyl acetate inhibits the reaction [TNF protein results in increased expression of and affects the localization of RELA protein modified form] |
CTD |
PMID:29276222 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sec14l2 |
SEC14-like lipid binding 2 |
multiple interactions |
ISO |
linalyl acetate inhibits the reaction [Testosterone results in increased expression of SEC14L2 mRNA] |
CTD |
PMID:31393563 |
|
NCBI chr14:78,973,805...78,998,480
Ensembl chr14:78,973,808...78,993,788
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
linalyl acetate inhibits the reaction [TNF protein results in increased expression of SELE mRNA] |
CTD |
PMID:29276222 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Selp |
selectin P |
multiple interactions |
ISO |
linalyl acetate inhibits the reaction [TNF protein results in increased expression of SELP mRNA] |
CTD |
PMID:29276222 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SNAI1 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of SOD1 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in decreased expression of TGFB1 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
linalyl acetate inhibits the reaction [TNF protein results in increased expression of and affects the localization of RELA protein modified form]; linalyl acetate inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; linalyl acetate inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; linalyl acetate inhibits the reaction [TNF protein results in increased expression of SELP mRNA]; linalyl acetate inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA] |
CTD |
PMID:29276222 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ugt2b34l1 |
UDP glucuronosyltransferase 2 family, polypeptide B34 like 1 |
multiple interactions |
ISO |
linalyl acetate inhibits the reaction [Testosterone results in increased expression of UGT2B28 mRNA] |
CTD |
PMID:31393563 |
|
NCBI chr14:21,146,140...21,167,706
Ensembl chr14:21,145,827...21,167,704
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
linalyl acetate inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA] |
CTD |
PMID:29276222 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB1 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
|
|
G |
Zeb2 |
zinc finger E-box binding homeobox 2 |
multiple interactions |
ISO |
[beta-thujone co-treated with linalyl acetate co-treated with sabinene co-treated with linalool co-treated with Camphor co-treated with myrcene co-treated with Eucalyptol co-treated with caryophyllene co-treated with spathulenol] results in increased expression of ZEB2 mRNA |
CTD |
PMID:38000518 |
|
NCBI chr 3:29,214,581...29,344,890
Ensembl chr 3:29,218,301...29,345,157
|
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions |
EXP |
[2,5-dihydro-2,4,5-trimethylthiazoline co-treated with 3-hexen-1-ol co-treated with 2-hexenal] results in decreased expression of POMC protein; [3-hexen-1-ol co-treated with 2-hexenal] inhibits the reaction [2,5-dihydro-2,4,5-trimethylthiazoline results in decreased expression of POMC protein]; [3-hexen-1-ol co-treated with 2-hexenal] results in decreased expression of POMC |
CTD |
PMID:19103229 PMID:21515296 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP |
4-hydroxyphenylethanol inhibits the reaction [Streptozocin results in increased activity of G6PC1 protein] |
CTD |
PMID:25641191 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
4-hydroxyphenylethanol inhibits the reaction [Streptozocin results in decreased activity of G6PD protein] |
CTD |
PMID:25641191 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
4-hydroxyphenylethanol inhibits the reaction [Streptozocin results in decreased expression of INS1 protein] |
CTD |
PMID:25641191 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
4-hydroxyphenylethanol inhibits the reaction [[Lipids results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone] |
CTD |
PMID:18081942 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
decreases expression |
ISO |
cathinone analog results in decreased expression of SLC6A3 mRNA |
CTD |
PMID:28173643 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
ISO |
acteoside results in decreased expression of ACTA2 protein |
CTD |
PMID:33522686 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
decreases expression multiple interactions |
ISO |
acteoside results in decreased expression of AGER mRNA; acteoside results in decreased expression of AGER protein acteoside inhibits the reaction [HMGB1 protein results in increased expression of AGER mRNA]; acteoside inhibits the reaction [HMGB1 protein results in increased expression of AGER protein] |
CTD |
PMID:33522686 PMID:36112883 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions decreases localization |
ISO |
acteoside promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased localization of AHR protein] acteoside results in decreased localization of AHR protein |
CTD |
PMID:21756928 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
increases localization |
ISO |
acteoside results in increased localization of ARNT protein |
CTD |
PMID:21756928 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression multiple interactions decreases secretion |
ISO |
acteoside results in decreased expression of CCL2 mRNA acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA] acteoside results in decreased secretion of CCL2 protein |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
acteoside results in decreased expression of CCND1 protein |
CTD |
PMID:17634406 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
acteoside results in decreased expression of CCND2 protein |
CTD |
PMID:17634406 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
acteoside results in decreased expression of CCND3 protein |
CTD |
PMID:17634406 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
acteoside results in decreased expression of CCNE1 protein |
CTD |
PMID:17634406 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdc42 |
cell division cycle 42 |
multiple interactions decreases expression |
ISO |
acteoside inhibits the reaction [HMGB1 protein results in increased expression of and results in increased activity of CDC42 protein]; acteoside inhibits the reaction [HMGB1 protein results in increased expression of CDC42 mRNA]; acteoside results in decreased expression of and results in decreased activity of CDC42 protein acteoside results in decreased expression of CDC42 mRNA |
CTD |
PMID:36112883 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
acteoside results in increased expression of CDH1 protein |
CTD |
PMID:33522686 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
acteoside results in decreased expression of and results in decreased activity of CDK2 protein |
CTD |
PMID:17634406 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases activity multiple interactions |
ISO |
acteoside results in decreased activity of CDK4 protein acteoside promotes the reaction [CDKN1A protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK4 protein] |
CTD |
PMID:17634406 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions |
ISO |
acteoside promotes the reaction [CDKN1A protein binds to CDK6 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK6 protein]; acteoside results in decreased expression of and results in decreased activity of CDK6 protein |
CTD |
PMID:17634406 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
acteoside results in increased expression of CDKN1A mRNA; acteoside results in increased expression of CDKN1A protein acteoside promotes the reaction [CDKN1A protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1A protein binds to CDK6 protein] |
CTD |
PMID:17634406 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
ISO |
acteoside results in increased expression of CDKN1B mRNA; acteoside results in increased expression of CDKN1B protein acteoside promotes the reaction [CDKN1B protein binds to CDK4 protein]; acteoside promotes the reaction [CDKN1B protein binds to CDK6 protein] |
CTD |
PMID:17634406 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
decreases secretion decreases expression multiple interactions |
ISO |
acteoside results in decreased secretion of CXCL10 protein acteoside results in decreased expression of CXCL10 mRNA acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein]; acteoside promotes the reaction [leptomycin B results in decreased secretion of CXCL10 protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
acteoside results in increased expression of CYP1A1 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
acteoside inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased activity of CYP2E1 protein] |
CTD |
PMID:14672760 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[acteoside results in decreased phosphorylation of RB1 protein] promotes the reaction [RB1 protein binds to E2F1 protein] |
CTD |
PMID:17634406 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases phosphorylation multiple interactions |
ISO |
acteoside results in decreased phosphorylation of EGFR protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein modified form]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Hmgb1 |
high mobility group box 1 |
decreases expression multiple interactions |
ISO |
acteoside results in decreased expression of HMGB1 mRNA; acteoside results in decreased expression of HMGB1 protein acteoside inhibits the reaction [HMGB1 protein results in increased expression of AGER mRNA]; acteoside inhibits the reaction [HMGB1 protein results in increased expression of AGER protein]; acteoside inhibits the reaction [HMGB1 protein results in increased expression of and results in increased activity of CDC42 protein]; acteoside inhibits the reaction [HMGB1 protein results in increased expression of CDC42 mRNA] |
CTD |
PMID:33522686 PMID:36112883 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
acteoside results in decreased expression of ICAM1 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
decreases expression multiple interactions |
ISO |
acteoside results in decreased expression of IFNG mRNA acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] |
CTD |
PMID:21371465 PMID:21756928 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO |
acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA] acteoside results in decreased expression of IL6 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
acteoside inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGB2 protein]; acteoside inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ITGB2 protein] |
CTD |
PMID:16393473 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions decreases phosphorylation |
ISO |
acteoside results in increased phosphorylation of MAPK1 protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein] acteoside results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO |
acteoside results in decreased phosphorylation of MAPK3 protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein] acteoside results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nox1 |
NADPH oxidase 1 |
decreases activity |
ISO |
acteoside results in decreased activity of NOX1 protein |
CTD |
PMID:16393473 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Ptgds |
prostaglandin D2 synthase |
affects binding |
ISO |
acteoside binds to PTGDS protein |
CTD |
PMID:26456343 |
|
NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:8,281,899...8,284,833
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[acteoside co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of PTGS2 mRNA |
CTD |
PMID:21756928 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rac1 |
Rac family small GTPase 1 |
decreases expression |
ISO |
Verbascoside decreases expression of RAC1 mRNA in colon cancer cells |
RGD |
PMID:29886834 |
RGD:153298971 |
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation multiple interactions |
ISO |
acteoside results in decreased phosphorylation of RB1 protein [acteoside results in decreased phosphorylation of RB1 protein] promotes the reaction [RB1 protein binds to E2F1 protein] |
CTD |
PMID:17634406 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases phosphorylation multiple interactions decreases phosphorylation |
ISO |
acteoside results in increased phosphorylation of RELA protein acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein] acteoside results in decreased phosphorylation of RELA protein |
CTD |
PMID:21756928 PMID:23527233 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Smad2 |
SMAD family member 2 |
increases phosphorylation |
ISO |
acteoside results in increased phosphorylation of SMAD2 protein |
CTD |
PMID:17634406 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smad3 |
SMAD family member 3 |
increases phosphorylation |
ISO |
acteoside results in increased phosphorylation of SMAD3 protein |
CTD |
PMID:17634406 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Smad7 |
SMAD family member 7 |
increases expression |
ISO |
acteoside results in increased expression of SMAD7 protein |
CTD |
PMID:33522686 |
|
NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
decreases expression |
ISO |
acteoside results in decreased expression of SNAI1 protein |
CTD |
PMID:33522686 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
decreases expression |
ISO |
acteoside results in decreased expression of SNAI2 protein |
CTD |
PMID:33522686 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression |
ISO |
acteoside results in decreased expression of SOD2 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
[acteoside co-treated with TGFA protein] results in increased expression of CXCL8 mRNA; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein modified form]; acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein] |
CTD |
PMID:21756928 PMID:21967610 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
acteoside results in increased expression of TGFB1 mRNA |
CTD |
PMID:17634406 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
decreases expression |
ISO |
acteoside results in decreased expression of TGFBR1 protein |
CTD |
PMID:33522686 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
decreases expression |
ISO |
acteoside results in decreased expression of TGFBR2 protein |
CTD |
PMID:33522686 |
|
NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL10 protein]; acteoside inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein] |
CTD |
PMID:21756928 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
decreases expression |
ISO |
acteoside results in decreased expression of VCAM1 mRNA |
CTD |
PMID:21371465 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases oxidation increases metabolic processing |
EXP ISO |
ALDH1A1 protein results in increased oxidation of benzaldehyde ALDH1A1 protein results in increased metabolism of benzaldehyde |
CTD |
PMID:10998257 PMID:21256123 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
increases metabolic processing multiple interactions |
ISO |
ALDH2 protein results in increased metabolism of benzaldehyde benzaldehyde inhibits the reaction [4-dimethylaminocinnamaldehyde binds to ALDH2 protein] |
CTD |
PMID:10609638 PMID:11744614 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
multiple interactions increases oxidation increases metabolic processing |
ISO |
[ALDH3A1 protein co-treated with NAD] results in increased oxidation of benzaldehyde; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of benzaldehyde; Cimetidine inhibits the reaction [ALDH3A1 protein results in increased oxidation of benzaldehyde] ALDH3A1 protein results in increased metabolism of benzaldehyde |
CTD |
PMID:10856427 PMID:21256123 PMID:21349255 PMID:23220590 PMID:25512087 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Aldh3b1 |
aldehyde dehydrogenase 3 family, member B1 |
affects binding |
ISO |
benzaldehyde binds to ALDH3B1 protein |
CTD |
PMID:20699116 |
|
NCBI chr 1:201,145,309...201,162,675
Ensembl chr 1:201,145,309...201,163,921
|
|
G |
Ar |
androgen receptor |
multiple interactions |
EXP |
benzaldehyde inhibits the reaction [Metribolone binds to AR protein] |
CTD |
PMID:3695475 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Or8a1b |
olfactory receptor family 8 subfamily A member 1B |
multiple interactions |
ISO |
benzaldehyde binds to and results in increased activity of OR8A1 protein |
CTD |
PMID:11943806 |
|
NCBI chr 8:37,434,903...37,435,832
Ensembl chr 8:37,434,551...37,439,746
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
increases activity multiple interactions |
ISO |
benzaldehyde results in increased activity of SLC2A1 protein [benzaldehyde co-treated with Glucose deficiency] results in decreased activity of SLC2A1 protein |
CTD |
PMID:20955755 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
increases expression |
ISO |
benzyl acetate results in increased expression of ENPP2 mRNA; benzyl acetate results in increased expression of ENPP2 protein |
CTD |
PMID:22952646 |
|
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
ISO |
benzyl acetate results in increased expression of MMP9 mRNA; benzyl acetate results in increased expression of MMP9 protein |
CTD |
PMID:22952646 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
multiple interactions |
ISO |
benzyl acetate results in increased cleavage of and results in increased activity of PPP3CA protein |
CTD |
PMID:22952646 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases oxidation |
ISO |
AKR1B1 protein results in increased oxidation of Benzyl Alcohol |
CTD |
PMID:17194029 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Benzyl Alcohol results in increased expression of IL1A protein |
CTD |
PMID:19878710 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
ISO |
Benzyl Alcohol results in increased expression of LIF protein |
CTD |
PMID:19878710 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases sulfation |
ISO |
SULT1A1 protein results in increased sulfation of Benzyl Alcohol |
CTD |
PMID:26663444 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult1b1 |
sulfotransferase family 1B member 1 |
increases sulfation |
ISO |
SULT1B1 protein results in increased sulfation of Benzyl Alcohol |
CTD |
PMID:26663444 |
|
NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
increases glucuronidation |
EXP |
UGT2B1 protein results in increased glucuronidation of Benzyl Alcohol |
CTD |
PMID:8302279 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
benzyl benzoate results in increased expression of ATF3 mRNA |
CTD |
PMID:27965148 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
benzyl benzoate results in increased expression of CD86 protein |
CTD |
PMID:29540657 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
benzyl benzoate inhibits the reaction [Estradiol binds to ESR1 protein] |
CTD |
PMID:19338011 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
benzyl benzoate inhibits the reaction [Estradiol binds to ESR2 protein] |
CTD |
PMID:19338011 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
benzyl benzoate results in decreased activity of MAOA protein |
CTD |
PMID:27270453 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Maob |
monoamine oxidase B |
decreases activity |
ISO |
benzyl benzoate results in decreased activity of MAOB protein |
CTD |
PMID:27270453 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Nefh |
neurofilament heavy chain |
affects expression |
EXP |
benzyl benzoate affects the expression of NEFH mRNA |
CTD |
PMID:22954530 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
benzyl benzoate results in increased expression of TFF1 mRNA |
CTD |
PMID:19338011 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
increases expression |
ISO |
benzyl cinnamate results in increased expression of AKR1C2 mRNA |
CTD |
PMID:20491607 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
benzyl cinnamate results in increased expression of CD86 protein |
CTD |
PMID:29540657 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
benzyl cinnamate results in increased expression of CYP1A1 mRNA |
CTD |
PMID:20491607 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Maff |
MAF bZIP transcription factor F |
increases expression |
ISO |
benzyl cinnamate results in increased expression of MAFF mRNA |
CTD |
PMID:20491607 |
|
NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
benzyl cinnamate results in decreased activity of MAOA protein |
CTD |
PMID:27270453 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Maob |
monoamine oxidase B |
decreases activity |
ISO |
benzyl cinnamate results in decreased activity of MAOB protein |
CTD |
PMID:27270453 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Mt1 |
metallothionein 1 |
increases expression |
ISO |
benzyl cinnamate results in increased expression of MT1A mRNA |
CTD |
PMID:20491607 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049
|
|
G |
Mt2A |
metallothionein 2A |
increases expression |
ISO |
benzyl cinnamate results in increased expression of MT2A mRNA |
CTD |
PMID:20491607 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
benzyl cinnamate results in increased expression of NQO1 mRNA |
CTD |
PMID:20491607 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
ISO |
benzyl cinnamate results in increased expression of TXN mRNA |
CTD |
PMID:20491607 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO |
benzylparaben results in increased expression of ADIPOQ mRNA |
CTD |
PMID:22956630 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Afp |
alpha-fetoprotein |
affects binding |
EXP |
benzylparaben binds to AFP protein |
CTD |
PMID:23013281 PMID:25349334 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
ISO |
benzylparaben results in increased expression of CEBPA mRNA |
CTD |
PMID:22956630 PMID:27659731 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
benzylparaben binds to and results in increased activity of ESR1 protein |
CTD |
PMID:23220609 PMID:23567241 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
benzylparaben binds to and results in increased activity of ESR2 protein |
CTD |
PMID:23567241 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrrg |
estrogen-related receptor gamma |
multiple interactions |
ISO |
benzylparaben inhibits the reaction [afimoxifene inhibits the reaction [ESRRG protein binds to NCOA2 protein]] |
CTD |
PMID:23583298 |
|
NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
|
|
G |
Faah |
fatty acid amide hydrolase |
decreases activity |
ISO EXP |
benzylparaben results in decreased activity of FAAH protein |
CTD |
PMID:27659731 |
|
NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO |
benzylparaben results in increased expression of FABP4 mRNA |
CTD |
PMID:22956630 PMID:27659731 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
benzylparaben results in increased expression of FASN mRNA |
CTD |
PMID:22956630 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Lep |
leptin |
decreases expression increases expression |
ISO |
benzylparaben results in decreased expression of LEP mRNA benzylparaben results in increased expression of LEP mRNA |
CTD |
PMID:22956630 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
benzylparaben inhibits the reaction [afimoxifene inhibits the reaction [ESRRG protein binds to NCOA2 protein]] |
CTD |
PMID:23583298 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression |
ISO |
benzylparaben results in increased expression of NR1I2 mRNA |
CTD |
PMID:31472229 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
benzylparaben results in increased activity of NR1I3 protein |
CTD |
PMID:28927721 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression |
EXP |
benzylparaben results in increased expression of PPARA mRNA |
CTD |
PMID:31472229 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression increases activity |
ISO |
benzylparaben results in increased expression of PPARG mRNA benzylparaben results in increased activity of PPARG protein |
CTD |
PMID:22956630 PMID:27659731 PMID:28527915 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding |
ISO |
benzylparaben binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057
|
|
|
G |
Calml5 |
calmodulin-like 5 |
increases expression |
ISO |
beta-damascenone results in increased expression of CALM4 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr17:66,394,433...66,395,352
|
|
G |
Casp14 |
caspase 14 |
increases expression affects localization |
ISO |
beta-damascenone results in increased expression of CASP14 mRNA beta-damascenone affects the localization of CASP14 protein |
CTD |
PMID:22982537 |
|
NCBI chr 7:10,929,759...10,932,591
Ensembl chr 7:10,926,725...10,933,405
|
|
G |
Ces3a |
carboxylesterase 3a |
increases expression |
ISO |
beta-damascenone results in increased expression of CES3 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr19:32,992,386...33,000,562
|
|
G |
Clca1 |
chloride channel accessory 1 |
increases expression |
ISO |
beta-damascenone results in increased expression of CLCA1 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369
|
|
G |
Clca2 |
chloride channel accessory 2 |
increases expression |
ISO |
beta-damascenone results in increased expression of CLCA2 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 2:233,993,619...234,022,691
Ensembl chr 2:233,995,078...234,022,199
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
ISO |
beta-damascenone results in increased expression of CYP17A1 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Fcgbp |
Fc gamma binding protein |
increases expression |
ISO |
beta-damascenone results in increased expression of FCGBP mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 1:83,374,979...83,413,082
Ensembl chr 1:83,372,127...83,413,083
|
|
G |
Flg |
filaggrin |
increases expression |
ISO |
beta-damascenone results in increased expression of FLG mRNA; beta-damascenone results in increased expression of FLG protein |
CTD |
PMID:22982537 |
|
NCBI chr 2:178,884,793...178,912,986
|
|
G |
Hrnr |
hornerin |
increases expression |
ISO |
beta-damascenone results in increased expression of HRNR mRNA |
CTD |
PMID:22982537 |
|
|
|
G |
Il20ra |
interleukin 20 receptor subunit alpha |
increases expression |
ISO |
beta-damascenone results in increased expression of IL20RA mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 1:14,424,215...14,494,226
Ensembl chr 1:14,451,228...14,493,602
|
|
G |
Il36rn |
interleukin 36 receptor antagonist |
increases expression |
ISO |
beta-damascenone results in increased expression of IL36RN mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 3:7,044,419...7,051,016
Ensembl chr 3:7,044,406...7,051,016
|
|
G |
Krt1 |
keratin 1 |
increases expression |
ISO |
beta-damascenone results in increased expression of KRT1 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Krt10 |
keratin 10 |
increases expression |
ISO |
beta-damascenone results in increased expression of KRT10 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701
|
|
G |
Lce1b |
late cornified envelope 1B |
increases expression |
ISO |
beta-damascenone results in increased expression of LCE1B mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 2:178,255,351...178,257,533
Ensembl chr 2:178,256,213...178,257,985
|
|
G |
Lce1f |
late cornified envelope 1F |
increases expression |
ISO |
beta-damascenone results in increased expression of LCE1F mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 2:178,305,786...178,307,372
Ensembl chr 2:178,305,786...178,307,372
|
|
G |
Lipm |
lipase, family member M |
increases expression |
ISO |
beta-damascenone results in increased expression of LIPM mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 1:231,618,145...231,637,599
Ensembl chr 1:231,618,284...231,637,410
|
|
G |
Loricrin |
loricrin cornified envelope precursor protein |
increases expression |
ISO |
beta-damascenone results in increased expression of LORICRIN mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 2:177,558,062...177,560,960
Ensembl chr 2:177,558,252...177,559,807
|
|
G |
Otop3 |
otopetrin 3 |
increases expression |
ISO |
beta-damascenone results in increased expression of OTOP3 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr10:100,577,346...100,588,729
Ensembl chr10:100,577,392...100,588,726
|
|
G |
Pla2g4f |
phospholipase A2, group IVF |
increases expression |
ISO |
beta-damascenone results in increased expression of PLA2G4F mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 3:107,249,053...107,266,201
Ensembl chr 3:107,250,075...107,264,689
|
|
G |
Plcxd1 |
phosphatidylinositol-specific phospholipase C, X domain containing 1 |
increases expression |
ISO |
beta-damascenone results in increased expression of PLCXD1 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr12:46,578,917...46,582,181
Ensembl chr12:46,579,225...46,582,392
|
|
G |
Sdr16c5 |
short chain dehydrogenase/reductase family 16C, member 5 |
increases expression |
ISO |
beta-damascenone results in increased expression of SDR16C5 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 5:17,018,813...17,043,974
Ensembl chr 5:17,018,813...17,040,970
|
|
G |
Susd2 |
sushi domain containing 2 |
increases expression |
ISO |
beta-damascenone results in increased expression of SUSD2 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr20:13,017,516...13,024,820
Ensembl chr20:13,017,477...13,024,903
|
|
G |
Tmprss4 |
transmembrane serine protease 4 |
increases expression |
ISO |
beta-damascenone results in increased expression of TMPRSS4 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 8:45,475,819...45,508,409
Ensembl chr 8:45,476,053...45,508,409
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
beta-ionone results in increased expression of BAX protein |
CTD |
PMID:31506784 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
beta-ionone results in decreased expression of BCL2 protein 3-methyladenine inhibits the reaction [beta-ionone results in decreased expression of BCL2 protein]; dorsomorphin inhibits the reaction [beta-ionone results in decreased expression of BCL2 protein]; Hydroxychloroquine inhibits the reaction [beta-ionone results in decreased expression of BCL2 protein]; STK11 protein affects the reaction [beta-ionone results in decreased expression of BCL2 protein] |
CTD |
PMID:23100158 PMID:31506784 PMID:36843289 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases expression |
ISO |
[alpha-Tocopherol co-treated with beta-ionone] results in increased activity of CASP3 protein beta-ionone results in increased cleavage of CASP3 protein beta-ionone results in increased expression of CASP3 protein modified form |
CTD |
PMID:17618090 PMID:23100158 PMID:31506784 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases cleavage |
ISO |
beta-ionone results in increased cleavage of CASP9 protein |
CTD |
PMID:36843289 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
beta-ionone results in decreased expression of CCND1 protein |
CTD |
PMID:15450939 PMID:31506784 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
beta-ionone results in decreased expression of CDK2 protein |
CTD |
PMID:15450939 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
beta-ionone results in decreased expression of CDK4 protein |
CTD |
PMID:15450939 PMID:31506784 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cryz |
crystallin zeta |
increases activity |
ISO |
beta-ionone results in increased activity of CRYZ protein |
CTD |
PMID:31506784 |
|
NCBI chr 2:243,552,037...243,580,369
Ensembl chr 2:243,552,119...243,579,758
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
beta-ionone promotes the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of HMGCR mRNA] |
CTD |
PMID:20435455 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Lmnb1 |
lamin B1 |
decreases farnesylation |
ISO |
beta-ionone results in decreased farnesylation of LMNB1 protein |
CTD |
PMID:10203554 |
|
NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [beta-ionone results in increased expression of and results in increased lipidation of MAP1LC3B protein]; beta-ionone results in increased expression of and results in increased lipidation of MAP1LC3B protein; STK11 protein affects the reaction [beta-ionone results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:36843289 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
beta-ionone results in increased phosphorylation of MAPK1 protein beta-ionone inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK1 protein modified form] |
CTD |
PMID:23268108 PMID:27226631 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
beta-ionone inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK3 protein modified form] beta-ionone results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:23268108 PMID:27226631 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
beta-ionone inhibits the reaction [Lipopolysaccharides affects the localization of NFKB1 protein] |
CTD |
PMID:23268108 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
beta-ionone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; beta-ionone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:23268108 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Olr59 |
olfactory receptor 59 |
multiple interactions |
ISO |
beta-ionone binds to and results in increased activity of OR51E2 protein |
CTD |
PMID:27226631 |
|
NCBI chr 1:157,193,051...157,227,707
Ensembl chr 1:157,193,080...157,211,179
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
3-methyladenine inhibits the reaction [beta-ionone results in increased cleavage of PARP1 protein]; dorsomorphin inhibits the reaction [beta-ionone results in increased cleavage of PARP1 protein]; Hydroxychloroquine inhibits the reaction [beta-ionone results in increased cleavage of PARP1 protein]; STK11 protein affects the reaction [beta-ionone results in increased cleavage of PARP1 protein] |
CTD |
PMID:36843289 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
beta-ionone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; beta-ionone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] beta-ionone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] |
CTD |
PMID:23268108 PMID:31506784 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
beta-ionone inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] |
CTD |
PMID:23268108 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Stk11 |
serine/threonine kinase 11 |
increases phosphorylation multiple interactions |
ISO |
beta-ionone results in increased phosphorylation of STK11 protein STK11 protein affects the reaction [beta-ionone results in decreased expression of BCL2 protein]; STK11 protein affects the reaction [beta-ionone results in increased cleavage of PARP1 protein]; STK11 protein affects the reaction [beta-ionone results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:36843289 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
beta-ionone inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; beta-ionone inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:23268108 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tyr |
tyrosinase |
increases expression |
ISO |
beta-ionone results in increased expression of TYR mRNA; beta-ionone results in increased expression of TYR protein |
CTD |
PMID:27226631 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
beta-myrcene results in decreased activity of CYP1A1 protein |
CTD |
PMID:34181028 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
EXP |
beta-myrcene results in decreased activity of CYP2B1 protein |
CTD |
PMID:9242356 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
|
G |
A4galt |
alpha 1,4-galactosyltransferase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of A4GALT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:114,368,525...114,392,872
Ensembl chr 7:114,368,276...114,396,071
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of ABCB1 protein |
CTD |
PMID:33965509 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of ABCC2 mRNA [dimethyl phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate] results in increased expression of ABCC2 mRNA |
CTD |
PMID:35739735 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of ABCC3 mRNA [dimethyl phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate] results in increased expression of ABCC3 mRNA |
CTD |
PMID:26519955 PMID:35739735 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions increases expression |
ISO |
[dimethyl phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate] results in increased expression of ABCC4 mRNA butylbenzyl phthalate results in increased expression of ABCC4 mRNA |
CTD |
PMID:35739735 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions increases expression |
EXP ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ABCG2 mRNA [dimethyl phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate] results in increased expression of ABCG2 mRNA butylbenzyl phthalate results in increased expression of ABCG2 mRNA |
CTD |
PMID:31199487 PMID:35739735 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ABCG5 mRNA |
CTD |
PMID:35739755 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ACACA protein; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ACACA mRNA |
CTD |
PMID:26820058 PMID:35739755 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acly |
ATP citrate lyase |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ACLY mRNA |
CTD |
PMID:35739755 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of ACOT1 mRNA |
CTD |
PMID:26519955 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ACOT2 protein |
CTD |
PMID:38995844 |
|
NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in decreased expression of ACOX1 mRNA |
CTD |
PMID:35739755 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ACTA2 mRNA; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ACTA2 protein |
CTD |
PMID:35739755 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of ADAMTS1 mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein affects the expression of ADAMTS1 mRNA] |
CTD |
PMID:33316053 PMID:37552060 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ADIPOQ mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ADIPOQ protein; [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of ADIPOQ mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of ADIPOQ protein; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]] butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; butylbenzyl phthalate promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein] |
CTD |
PMID:26820058 PMID:28595985 PMID:31016361 PMID:32407875 PMID:34864131 PMID:37021957 PMID:38954831 More...
|
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of ADRB3 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects localization affects activity increases expression multiple interactions |
ISO |
butylbenzyl phthalate affects the localization of AHR protein butylbenzyl phthalate affects the activity of AHR protein butylbenzyl phthalate results in increased expression of AHR mRNA; butylbenzyl phthalate results in increased expression of AHR protein 3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of AHR mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of AHR protein]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT mRNA]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT protein]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 mRNA]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 protein]; butylbenzyl phthalate binds to and results in increased activity of AHR protein; butylbenzyl phthalate promotes the reaction [AHR protein binds to ARNT protein]; butylbenzyl phthalate promotes the reaction [AHR protein binds to CYP1B1 promoter] |
CTD |
PMID:18294747 PMID:22138065 PMID:23220035 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ak5 |
adenylate kinase 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of AK5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions decreases phosphorylation affects phosphorylation |
ISO EXP |
butylbenzyl phthalate results in increased phosphorylation of AKT1 protein [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased phosphorylation of AKT1 protein butylbenzyl phthalate results in decreased phosphorylation of AKT1 protein butylbenzyl phthalate affects the phosphorylation of AKT1 protein HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:22552774 PMID:29864457 PMID:31319113 PMID:33395283 PMID:35739755 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
increases phosphorylation multiple interactions |
EXP ISO |
butylbenzyl phthalate results in increased phosphorylation of AKT2 protein [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased phosphorylation of AKT2 protein |
CTD |
PMID:31319113 PMID:35739755 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Akt3 |
AKT serine/threonine kinase 3 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased phosphorylation of AKT3 protein |
CTD |
PMID:35739755 |
|
NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:30768133 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ALDOC mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ALDOC protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ALPL protein |
CTD |
PMID:35739755 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Amh |
anti-Mullerian hormone |
multiple interactions increases expression |
EXP |
[butylbenzyl phthalate co-treated with 4-vinyl-1-cyclohexene dioxide] results in decreased expression of AMH mRNA; [butylbenzyl phthalate co-treated with Dibutyl Phthalate] results in decreased expression of AMH mRNA; butylbenzyl phthalate promotes the reaction [4-vinyl-1-cyclohexene dioxide results in decreased expression of AMH protein] butylbenzyl phthalate results in increased expression of AMH mRNA; butylbenzyl phthalate results in increased expression of AMH protein |
CTD |
PMID:29969652 PMID:31319113 |
|
NCBI chr 7:8,906,776...8,909,192
Ensembl chr 7:8,906,836...8,909,282
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of ANGPT2 protein |
CTD |
PMID:38954831 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Angptl3 |
angiopoietin-like 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of ANGPTL3 protein |
CTD |
PMID:38954831 |
|
NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of APAF1 mRNA |
CTD |
PMID:37364641 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Ar |
androgen receptor |
multiple interactions affects binding affects activity decreases activity |
ISO EXP |
butylbenzyl phthalate inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; butylbenzyl phthalate inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; butylbenzyl phthalate inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; butylbenzyl phthalate inhibits the reaction [Stanozolol binds to and results in increased activity of AR protein] butylbenzyl phthalate binds to AR protein butylbenzyl phthalate affects the activity of AR protein butylbenzyl phthalate results in decreased activity of AR protein |
CTD |
PMID:9846162 PMID:14565775 PMID:15840436 PMID:18294747 PMID:20943248 PMID:28571686 PMID:29162470 PMID:33049310 More...
|
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions increases expression |
ISO |
3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT protein]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT mRNA]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT protein]; butylbenzyl phthalate promotes the reaction [AHR protein binds to ARNT protein] butylbenzyl phthalate results in increased expression of ARNT mRNA; butylbenzyl phthalate results in increased expression of ARNT protein |
CTD |
PMID:22138065 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions decreases expression |
ISO EXP |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [butylbenzyl phthalate results in decreased expression of ARNT2 mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ARNT2 mRNA |
CTD |
PMID:21771643 PMID:31199487 |
|
NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153
|
|
G |
Astn1 |
astrotactin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:70,537,423...70,855,440
Ensembl chr13:70,537,703...70,855,440
|
|
G |
Astn2 |
astrotactin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:78,758,142...79,744,021
Ensembl chr 5:78,758,142...79,748,273
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of ATF4 mRNA |
CTD |
PMID:37364641 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atm |
ATM serine/threonine kinase |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of ATM protein ATM protein affects the reaction [butylbenzyl phthalate results in increased expression of ZEB1 protein] |
CTD |
PMID:31212022 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of ATP1A1 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Atp6v1c2 |
ATPase H+ transporting V1 subunit C2 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of ATP6V1C2 mRNA |
CTD |
PMID:36756972 |
|
NCBI chr 6:40,080,545...40,144,199
Ensembl chr 6:40,080,547...40,120,028
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of BAK1 mRNA |
CTD |
PMID:37364641 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of BAX protein; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of BAX protein; [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of BAX mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BAX mRNA |
CTD |
PMID:28013214 PMID:35739755 PMID:37021957 PMID:37364641 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BCAT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases methylation increases expression |
ISO EXP |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in decreased expression of BCL2 protein; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of BCL2 protein; [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of BCL2 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of BCL2 mRNA butylbenzyl phthalate results in decreased methylation of BCL2 promoter butylbenzyl phthalate results in increased expression of BCL2 mRNA |
CTD |
PMID:28013214 PMID:31016752 PMID:35487445 PMID:35739755 PMID:35762964 PMID:37021957 PMID:37364641 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l10 |
Bcl2-like 10 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of BCL2L10 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 8:76,107,326...76,113,373
Ensembl chr 8:76,107,326...76,113,367
|
|
G |
Bend6 |
BEN domain containing 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BEND6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:36,081,033...36,135,309
Ensembl chr 9:36,081,484...36,135,228
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of BMP6 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bpgm |
bisphosphoglycerate mutase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BPGM mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:63,139,730...63,168,581
Ensembl chr 4:63,140,018...63,168,581
|
|
G |
C5 |
complement C5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of C5 protein |
CTD |
PMID:38954831 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
Cacng7 |
calcium voltage-gated channel auxiliary subunit gamma 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CACNG7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:65,800,059...65,831,246
Ensembl chr 1:65,800,355...65,831,006
|
|
G |
Cadm3 |
cell adhesion molecule 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADM3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:85,784,785...85,817,412
Ensembl chr13:85,786,483...85,817,749
|
|
G |
Cadps |
calcium dependent secretion activator |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADPS mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:12,289,803...12,742,786
Ensembl chr15:12,290,262...12,742,779
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAMK4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CASP2 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of CASP3 protein alternative form [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of CASP3 protein; [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CASP3 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in increased expression of and results in increased activity of CASP3 protein; butylbenzyl phthalate results in increased expression of and results in increased activity of CASP3 protein |
CTD |
PMID:23220035 PMID:29029336 PMID:35739755 PMID:37839492 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of CASP8 protein; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of CASP8 protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CASP8 mRNA |
CTD |
PMID:28013214 PMID:35739755 PMID:37364641 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of CASP9 protein |
CTD |
PMID:35739755 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of CAT mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAT mRNA |
CTD |
PMID:28013214 PMID:37364641 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CCL2 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CCL5 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases methylation increases expression |
ISO |
MIR19A mRNA affects the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein] butylbenzyl phthalate results in decreased methylation of CCND1 promoter butylbenzyl phthalate results in increased expression of CCND1 mRNA; butylbenzyl phthalate results in increased expression of CCND1 protein |
CTD |
PMID:29864457 PMID:30243731 PMID:31016752 PMID:35487445 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CCND2 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cd93 |
CD93 molecule |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of CD93 protein |
CTD |
PMID:38954831 |
|
NCBI chr 3:135,891,859...135,898,378
Ensembl chr 3:135,891,859...135,898,378
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of CDH1 protein [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of CDH1 protein |
CTD |
PMID:22552774 PMID:37364641 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CDK4 mRNA |
CTD |
PMID:35762964 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression multiple interactions |
ISO EXP |
butylbenzyl phthalate results in decreased expression of CDKN1A mRNA; butylbenzyl phthalate results in decreased expression of CDKN1A protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CDKN1A mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of CDKN1A mRNA] MIR19A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein] |
CTD |
PMID:29864457 PMID:30243731 PMID:33316053 PMID:35762964 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CDKN1B mRNA |
CTD |
PMID:37839492 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions increases methylation decreases expression |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA butylbenzyl phthalate results in increased methylation of CDKN2A promoter butylbenzyl phthalate results in decreased expression of CDKN2A mRNA |
CTD |
PMID:28013214 PMID:35487445 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CEBPA protein; [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CEBPA mRNA; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]] |
CTD |
PMID:26820058 PMID:28595985 PMID:37021957 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CELSR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:109,530,597...109,558,360
Ensembl chr 8:109,530,641...109,558,354
|
|
G |
Cfd |
complement factor D |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CFD mRNA |
CTD |
PMID:26820058 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein affects the expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CXCR4 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CYP11A1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of HSD3B2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PTX3 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of RGS2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of STAR mRNA]; butylbenzyl phthalate inhibits the reaction [CGA protein results in increased secretion of Dinoprostone]; butylbenzyl phthalate inhibits the reaction [CGA protein results in increased secretion of Progesterone]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of EDN2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of MMP9 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PGR mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PLAT mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of CDKN1A mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of IL6 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PTGS2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINB2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINE1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of TIMP1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of WNT4 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP14 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP16 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of SLCO2A1 mRNA] |
CTD |
PMID:25016925 PMID:33316053 PMID:37552060 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chga |
chromogranin A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGA mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
|
|
G |
Chgb |
chromogranin B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGB mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:120,043,824...120,057,169
Ensembl chr 3:120,043,738...120,057,166
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of CHRNA3 mRNA |
CTD |
PMID:36746855 |
|
NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Cited1 |
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CITED1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:67,350,376...67,355,072
Ensembl chr X:67,350,373...67,355,162
|
|
G |
Clstn3 |
calsyntenin 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CLSTN3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cntnap1 |
contactin associated protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CNTNAP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:86,109,850...86,125,612
Ensembl chr10:86,111,643...86,125,611
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of COL18A1 protein |
CTD |
PMID:38954831 |
|
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Comt |
catechol-O-methyltransferase |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of COMT mRNA fulvestrant inhibits the reaction [butylbenzyl phthalate results in decreased expression of COMT mRNA] |
CTD |
PMID:24040167 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CPT1A mRNA |
CTD |
PMID:35739755 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CPT1B mRNA |
CTD |
PMID:35739755 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CPT2 mRNA |
CTD |
PMID:35739755 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CRH mRNA |
CTD |
PMID:32518293 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CRHR1 mRNA |
CTD |
PMID:32518293 |
|
NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481
|
|
G |
Crisp1 |
cysteine-rich secretory protein 1 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of CRISP1 mRNA |
CTD |
PMID:36756972 |
|
NCBI chr 9:20,741,775...20,768,796
Ensembl chr 9:20,741,777...20,768,796
|
|
G |
Crmp1 |
collapsin response mediator protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CRMP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:73,509,933...73,556,192
Ensembl chr14:73,509,933...73,556,177
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CRP protein |
CTD |
PMID:38954831 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of CSF1 protein |
CTD |
PMID:38954831 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Ctnnb1 |
catenin beta 1 |
affects localization increases acetylation multiple interactions |
ISO |
butylbenzyl phthalate affects the localization of CTNNB1 protein butylbenzyl phthalate results in increased acetylation of CTNNB1 protein HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate affects the localization of CTNNB1 protein]; trichostatin A inhibits the reaction [butylbenzyl phthalate affects the localization of CTNNB1 protein] |
CTD |
PMID:22552774 PMID:27923775 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of CXCL12 protein |
CTD |
PMID:38954831 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl13 |
C-X-C motif chemokine ligand 13 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of CXCL13 protein |
CTD |
PMID:38954831 |
|
NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of CXCL1 mRNA |
CTD |
PMID:35739755 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CXCR4 mRNA] |
CTD |
PMID:37552060 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of CYBA mRNA |
CTD |
PMID:35739755 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of CYBB mRNA |
CTD |
PMID:35739755 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of CYCS protein |
CTD |
PMID:35739755 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression multiple interactions |
EXP ISO |
butylbenzyl phthalate results in increased expression of CYP11A1 mRNA; butylbenzyl phthalate results in increased expression of CYP11A1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CYP11A1 mRNA] [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP11A1 mRNA [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CYP11A1 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11A1 mRNA; [dimethyl phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:26472102 PMID:28013214 PMID:29029336 PMID:30802670 PMID:31319113 PMID:32518293 PMID:34597818 PMID:35739735 PMID:37552060 PMID:37788136 More...
|
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of CYP11B1 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP ISO |
butylbenzyl phthalate results in decreased expression of CYP17A1 mRNA [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP17A1 mRNA [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in increased expression of CYP17A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:26472102 PMID:29029336 PMID:30802670 PMID:33983380 PMID:37788136 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions increases expression decreases expression decreases activity |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP19A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in decreased expression of CYP19A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in decreased expression of CYP19A1 protein; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP19A1 mRNA; schizandrin B inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP19A1 mRNA]; schizandrin B inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP19A1 protein] butylbenzyl phthalate results in increased expression of CYP19A1 mRNA; butylbenzyl phthalate results in increased expression of CYP19A1 protein butylbenzyl phthalate results in increased expression of and results in increased activity of CYP19A1 protein; Fulvestrant inhibits the reaction [butylbenzyl phthalate results in increased activity of CYP19A1 protein] butylbenzyl phthalate results in decreased expression of CYP19A1 mRNA; butylbenzyl phthalate results in decreased expression of CYP19A1 protein butylbenzyl phthalate results in decreased activity of CYP19A1 protein |
CTD |
PMID:27825933 PMID:28013214 PMID:29029336 PMID:31016752 PMID:34597818 PMID:38227285 More...
|
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression decreases activity |
ISO EXP |
butylbenzyl phthalate results in increased expression of CYP1A1 protein butylbenzyl phthalate results in decreased activity of CYP1A1 protein |
CTD |
PMID:22138065 PMID:27432241 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
EXP |
butylbenzyl phthalate results in decreased activity of CYP1A2 protein |
CTD |
PMID:27432241 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 protein]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 mRNA]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 protein]; butylbenzyl phthalate promotes the reaction [AHR protein binds to CYP1B1 promoter] schizandrin B inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 mRNA] butylbenzyl phthalate results in increased expression of CYP1B1 mRNA; butylbenzyl phthalate results in increased expression of CYP1B1 protein |
CTD |
PMID:22138065 PMID:38227285 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
[diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in increased expression of CYP26B1 mRNA |
CTD |
PMID:37788136 |
|
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of CYP27A1 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
EXP |
butylbenzyl phthalate results in decreased activity of CYP2B1 protein |
CTD |
PMID:27432241 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of CYP2B10 mRNA |
CTD |
PMID:26519955 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity |
EXP |
butylbenzyl phthalate results in decreased activity of CYP2C11 protein |
CTD |
PMID:27432241 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
EXP |
butylbenzyl phthalate results in decreased activity of CYP2E1 protein |
CTD |
PMID:27432241 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of CYP3A4 protein |
CTD |
PMID:33965509 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity |
EXP |
butylbenzyl phthalate results in decreased activity of CYP3A62 protein |
CTD |
PMID:27432241 |
|
NCBI chr12:16,397,998...16,433,833
Ensembl chr12:16,397,998...16,433,833
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate] affects the expression of CYP4F18 protein |
CTD |
PMID:38995844 |
|
NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of CYP51 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Dclk3 |
doublecortin-like kinase 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DCLK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:111,401,544...111,453,999
Ensembl chr 8:111,401,358...111,453,999
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DDC mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of DDIT3 mRNA |
CTD |
PMID:37364641 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of DHCR7 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dhx8 |
DEAH-box helicase 8 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate] affects the expression of DHX8 protein |
CTD |
PMID:38995844 |
|
NCBI chr10:86,667,641...86,704,198
Ensembl chr10:86,667,834...86,705,137
|
|
G |
Dock3 |
dedicator of cyto-kinesis 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DOCK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:107,552,462...107,903,527
Ensembl chr 8:107,552,463...107,903,514
|
|
G |
Dpf1 |
double PHD fingers 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DPF1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:84,602,212...84,615,954
Ensembl chr 1:84,602,336...84,615,950
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of EBP mRNA |
CTD |
PMID:26472102 |
|
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Ece2 |
endothelin-converting enzyme 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ECE2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:80,259,130...80,278,446
Ensembl chr11:80,263,162...80,278,428
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EDN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn2 |
endothelin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of EDN2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
fulvestrant inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of EGFR protein] |
CTD |
PMID:22552774 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Elmod1 |
ELMO domain containing 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ELMOD1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:54,298,363...54,355,140
|
|
G |
Emx2 |
empty spiracles homeobox 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EMX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:258,626,584...258,633,594
Ensembl chr 1:258,626,584...258,633,594
|
|
G |
Epdr1 |
ependymin related 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EPDR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:45,333,932...45,358,597
Ensembl chr17:45,333,956...45,358,594
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of ERN1 mRNA; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of ERN1 protein |
CTD |
PMID:37364641 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Espn |
espin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESPN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:162,626,560...162,660,439
Ensembl chr 5:162,626,560...162,660,256
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression increases activity affects binding decreases methylation |
ISO EXP |
butylbenzyl phthalate binds to and results in increased activity of ESR1 protein; butylbenzyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; Oxygen deficiency promotes the reaction [butylbenzyl phthalate results in decreased expression of ESR1 mRNA]; Oxygen deficiency promotes the reaction [butylbenzyl phthalate results in decreased expression of ESR1 protein]; Tamoxifen inhibits the reaction [butylbenzyl phthalate binds to and results in increased activity of ESR1 protein] [Zeranol co-treated with butylbenzyl phthalate] affects the expression of ESR1 protein butylbenzyl phthalate results in decreased expression of ESR1 mRNA; butylbenzyl phthalate results in decreased expression of ESR1 protein butylbenzyl phthalate results in increased activity of ESR1 protein [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ESR1 protein; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of ESR1 protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESR1 mRNA butylbenzyl phthalate binds to ESR1 protein butylbenzyl phthalate results in decreased methylation of ESR1 gene; butylbenzyl phthalate results in decreased methylation of ESR1 promoter |
CTD |
PMID:15840436 PMID:16326419 PMID:19913605 PMID:20822795 PMID:22467034 PMID:22949852 PMID:28013214 PMID:28571686 PMID:29162470 PMID:30851587 PMID:33049310 PMID:35163327 PMID:35739755 PMID:37364641 More...
|
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases expression increases activity affects binding |
ISO |
butylbenzyl phthalate binds to and results in decreased activity of ESR2 protein; butylbenzyl phthalate binds to and results in increased activity of ESR2 protein; butylbenzyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR2 protein] butylbenzyl phthalate results in increased expression of ESR2 mRNA [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of ESR2 protein; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of ESR2 protein; [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ESR2 mRNA butylbenzyl phthalate results in increased activity of ESR2 protein butylbenzyl phthalate binds to ESR2 protein |
CTD |
PMID:15840436 PMID:19913605 PMID:28571686 PMID:31016752 PMID:32518293 PMID:35739755 PMID:37364641 More...
|
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
multiple interactions |
ISO |
butylbenzyl phthalate promotes the reaction [ETS1 protein binds to MMP3 promoter]; butylbenzyl phthalate promotes the reaction [NR1I2 protein binds to ETS1 protein]; butylbenzyl phthalate results in increased localization of and results in increased activity of ETS1 protein |
CTD |
PMID:33965509 |
|
NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of FABP4 mRNA [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FABP4 mRNA |
CTD |
PMID:24155963 PMID:26820058 PMID:27923775 PMID:34520170 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FABP5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fam163a |
family with sequence similarity 163, member A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FAM163A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:68,262,867...68,341,323
Ensembl chr13:68,262,872...68,341,049
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FASN mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FASN protein; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of FASN mRNA |
CTD |
PMID:26820058 PMID:35739755 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FEZ1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of FGF2 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of FGFR2 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FKBP1B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FKBP5 mRNA |
CTD |
PMID:32518293 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Flg |
filaggrin |
multiple interactions |
ISO |
[FLG gene polymorphism affects the susceptibility to butylbenzyl phthalate] which affects the abundance of mono-benzyl phthalate |
CTD |
PMID:24380925 |
|
NCBI chr 2:178,884,793...178,912,986
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of and results in increased acetylation of FOXO1 protein |
CTD |
PMID:27923775 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fsd2 |
fibronectin type III and SPRY domain containing 2 |
increases expression decreases expression |
EXP |
butylbenzyl phthalate results in increased expression of FSD2 mRNA butylbenzyl phthalate results in decreased expression of FSD2 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 1:135,484,002...135,522,517
Ensembl chr 1:135,489,266...135,522,472
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions increases expression |
EXP ISO |
butylbenzyl phthalate promotes the reaction [Dibutyl Phthalate results in increased expression of FSHB protein] [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of FSHB protein butylbenzyl phthalate results in increased expression of FSHB protein |
CTD |
PMID:29969652 PMID:34597818 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions increases expression |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FSHR mRNA butylbenzyl phthalate results in increased expression of FSHR mRNA; butylbenzyl phthalate results in increased expression of FSHR protein |
CTD |
PMID:28013214 PMID:31319113 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Fxyd7 |
FXYD domain-containing ion transport regulator 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FXYD7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:86,277,678...86,286,954
Ensembl chr 1:86,277,678...86,286,954
|
|
G |
Gabpb1 |
GA binding protein transcription factor subunit beta 1 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of GABPB1 mRNA |
CTD |
PMID:26520405 |
|
NCBI chr 3:113,879,972...113,924,742
Ensembl chr 3:113,879,973...113,923,696
|
|
G |
Gata4 |
GATA binding protein 4 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of GATA4 mRNA |
CTD |
PMID:37364641 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of GCLC mRNA |
CTD |
PMID:37364641 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gfra3 |
GDNF family receptor alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:26,297,828...26,326,105
Ensembl chr18:26,297,829...26,326,105
|
|
G |
Gfra4 |
GDNF family receptor alpha 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:118,254,937...118,262,252
Ensembl chr 3:118,255,402...118,258,329
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of GGT1 protein |
CTD |
PMID:35739755 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Ggta1 |
glycoprotein alpha-galactosyltransferase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GGTA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:18,732,985...18,824,916
Ensembl chr 3:18,732,991...18,809,908
|
|
G |
Gk |
glycerol kinase |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of GK mRNA |
CTD |
PMID:35739755 |
|
NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631
|
|
G |
Gls2 |
glutaminase 2 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of GLS2 mRNA |
CTD |
PMID:37364641 |
|
NCBI chr 7:617,252...633,424
Ensembl chr 7:617,288...633,426
|
|
G |
Gng2 |
G protein subunit gamma 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GNG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:4,316,038...4,416,918
Ensembl chr15:4,316,059...4,417,183
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of GOT1 protein |
CTD |
PMID:35739755 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gper1 |
G protein-coupled estrogen receptor 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of GPER1 protein; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of GPER1 mRNA |
CTD |
PMID:35739755 PMID:37364641 |
|
NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889
|
|
G |
Gpi |
glucose-6-phosphate isomerase |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of GPI1 mRNA |
CTD |
PMID:37364641 |
|
NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of GPT protein |
CTD |
PMID:35739755 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of GPX1 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GPX1 mRNA |
CTD |
PMID:28013214 PMID:37021957 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Grb14 |
growth factor receptor bound protein 14 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of GRB14 mRNA |
CTD |
PMID:15728792 |
|
NCBI chr 3:49,568,210...49,683,805
Ensembl chr 3:49,568,210...49,683,889
|
|
G |
Greb1 |
growth regulating estrogen receptor binding 1 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of GREB1 mRNA |
CTD |
PMID:35307500 |
|
NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIN2B mRNA |
CTD |
PMID:32518293 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation |
ISO |
HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:22552774 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSTA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
H19 |
H19 imprinted maternally expressed transcript |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of H19 mRNA |
CTD |
PMID:33395283 |
|
NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases phosphorylation |
ISO |
Nicotinamide Mononucleotide inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of H2AX protein] |
CTD |
PMID:36756972 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hdac6 |
histone deacetylase 6 |
multiple interactions increases response to substance increases expression |
ISO |
[butylbenzyl phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter]] which results in increased expression of HDAC6 mRNA; butylbenzyl phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate affects the localization of CTNNB1 protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in decreased expression of KRT7 protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of VIM protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of AKT1 protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of GSK3B protein]; TFAP2A mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of HDAC6 protein] HDAC6 results in increased susceptibility to butylbenzyl phthalate butylbenzyl phthalate results in increased expression of HDAC6 mRNA; butylbenzyl phthalate results in increased expression of HDAC6 protein |
CTD |
PMID:22552774 |
|
NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of HEY1 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 2:93,096,605...93,100,316
Ensembl chr 2:93,095,498...93,100,312
|
|
G |
Hk1 |
hexokinase 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of HK1 mRNA |
CTD |
PMID:37364641 |
|
NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of HMGCR mRNA |
CTD |
PMID:35739755 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of HMOX1 mRNA |
CTD |
PMID:37364641 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf1a |
HNF1 homeobox A |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of HNF1A mRNA |
CTD |
PMID:15728792 |
|
NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104
|
|
G |
Hoxb8 |
homeo box B8 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXB8 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:81,248,313...81,251,261
Ensembl chr10:81,248,887...81,250,638
|
|
G |
Hoxd3 |
homeo box D3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXD3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:59,638,708...59,650,282
Ensembl chr 3:59,638,708...59,650,282
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate] results in increased expression of HPGD mRNA; [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate] results in increased expression of HPGD protein |
CTD |
PMID:38995844 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of HSD11B1 protein |
CTD |
PMID:31319113 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hsd17b11 |
hydroxysteroid (17-beta) dehydrogenase 11 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of HSD17B11 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr14:5,693,304...5,743,157
Ensembl chr14:5,711,964...5,743,161
|
|
G |
Hsd17b8 |
hydroxysteroid (17-beta) dehydrogenase 8 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of HSD17B8 mRNA |
CTD |
PMID:19560483 PMID:26472102 |
|
NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions increases expression |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSD3B1 mRNA; [dimethyl phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate] results in increased expression of HSD3B1 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of HSD3B1 mRNA butylbenzyl phthalate results in increased expression of HSD3B1 mRNA; butylbenzyl phthalate results in increased expression of HSD3B1 protein |
CTD |
PMID:28013214 PMID:31319113 PMID:35739735 PMID:35762964 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of HSD3B2 mRNA] |
CTD |
PMID:37552060 |
|
NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Hsd3b3 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 3 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of HSD3B3 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 2:186,138,044...186,144,024
Ensembl chr 2:186,138,044...186,144,033
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of HSP90B1 mRNA |
CTD |
PMID:37364641 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa12a |
heat shock protein family A (Hsp70) member 12A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSPA12A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:257,935,642...258,096,602
Ensembl chr 1:257,935,644...258,096,846
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of HSPA5 mRNA; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of HSPA5 protein |
CTD |
PMID:37364641 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of HTR1A mRNA |
CTD |
PMID:32518293 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of HTR2A mRNA |
CTD |
PMID:32518293 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Htr2c |
5-hydroxytryptamine receptor 2C |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of HTR2C mRNA |
CTD |
PMID:36746855 |
|
NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of ID1 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Ido2 |
indoleamine 2,3-dioxygenase 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of IDO2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr16:67,459,158...67,498,052
Ensembl chr16:67,459,190...67,496,324
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of IFNG protein |
CTD |
PMID:38954831 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of IGF1 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of IGFBP2 protein |
CTD |
PMID:38954831 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Igfbp6 |
insulin-like growth factor binding protein 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of IGFBP6 protein |
CTD |
PMID:38954831 |
|
NCBI chr 7:133,276,309...133,280,944
Ensembl chr 7:133,276,234...133,280,966
|
|
G |
Igfbp7 |
insulin-like growth factor binding protein 7 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of IGFBP7 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in decreased expression of IL10 mRNA |
CTD |
PMID:35739755 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il11 |
interleukin 11 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of IL11 mRNA |
CTD |
PMID:36746855 |
|
NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129
|
|
G |
Il12a |
interleukin 12A |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of IL12A mRNA |
CTD |
PMID:36746855 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in decreased expression of IL13 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of IL13 protein |
CTD |
PMID:35739755 PMID:38954831 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of IL1B mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in decreased expression of IL4 mRNA |
CTD |
PMID:35739755 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of IL6 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of IL6 mRNA] |
CTD |
PMID:33316053 PMID:35739755 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inha |
inhibin subunit alpha |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of INHA mRNA |
CTD |
PMID:26472102 PMID:33983380 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
butylbenzyl phthalate promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein] |
CTD |
PMID:32407875 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] affects the abundance of diphosphoric acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of carbamic acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Cholesterol analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Cystathionine analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Desmosterol analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of ethylamine analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Glycine analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Inositol analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of methylphosphate analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of monoethyl phosphate analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of n-butylamine analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Palmitic Acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of phosphoric acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Pyrrolidonecarboxylic Acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of sebacic acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of stearic acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of undecane analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ACACA protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ADIPOQ mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ADIPOQ protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CEBPA protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CFD mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FABP4 mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FASN mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FASN protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of LPL mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PLIN1 protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PPARG mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PPARG protein; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Triglycerides]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TNF mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Triglycerides]]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TNF mRNA]] butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased secretion of TNFRSF11B protein]; butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein] |
CTD |
PMID:26820058 PMID:28595985 PMID:31016361 PMID:34864131 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insig1 |
insulin induced gene 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of INSIG1 mRNA |
CTD |
PMID:15728792 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Insl3 |
insulin-like 3 |
decreases expression multiple interactions |
EXP |
butylbenzyl phthalate results in decreased expression of INSL3 mRNA [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of INSL3 mRNA |
CTD |
PMID:14687758 PMID:16102138 PMID:18411233 PMID:33983380 PMID:37788136 |
|
NCBI chr16:18,398,682...18,400,566
Ensembl chr16:18,384,829...18,400,560
|
|
G |
Ints13 |
integrator complex subunit 13 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate] affects the expression of INTS13 protein |
CTD |
PMID:38995844 |
|
NCBI chr 4:179,459,740...179,491,541
Ensembl chr 4:179,459,740...179,491,541
|
|
G |
Irs1 |
insulin receptor substrate 1 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of IRS1 mRNA |
CTD |
PMID:33395283 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Kif18b |
kinesin family member 18B |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of KIF18B mRNA |
CTD |
PMID:36756972 |
|
NCBI chr10:87,870,424...87,889,895
Ensembl chr10:87,870,428...87,889,850
|
|
G |
Kif5a |
kinesin family member 5A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of KIF5A protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of KIF5A mRNA |
CTD |
PMID:37690569 |
|
NCBI chr 7:63,051,894...63,089,024
Ensembl chr 7:63,049,424...63,092,858
|
|
G |
Kif5c |
kinesin family member 5C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of KIF5C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
Krt7 |
keratin 7 |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of KRT7 protein HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in decreased expression of KRT7 protein] |
CTD |
PMID:22552774 |
|
NCBI chr 7:132,528,881...132,545,052
Ensembl chr 7:132,528,895...132,545,052
|
|
G |
L1cam |
L1 cell adhesion molecule |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of L1CAM mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of L1CAM protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr X:151,597,270...151,623,776
Ensembl chr X:151,597,277...151,623,857
|
|
G |
Lamp3 |
lysosomal-associated membrane protein 3 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of LAMP3 mRNA |
CTD |
PMID:20678512 |
|
NCBI chr11:81,153,491...81,224,643
Ensembl chr11:81,193,649...81,221,784
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
EXP ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LCN2 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of LCN2 protein |
CTD |
PMID:31199487 PMID:38954831 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldlr |
low density lipoprotein receptor |
decreases expression multiple interactions |
EXP ISO |
butylbenzyl phthalate results in decreased expression of LDLR mRNA [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of LDLR mRNA |
CTD |
PMID:15728792 PMID:35739755 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
multiple interactions |
ISO |
butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]]; trichostatin A inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]] |
CTD |
PMID:22552774 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of LEP protein |
CTD |
PMID:38954831 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased secretion of LHB protein; [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in decreased secretion of LHB protein |
CTD |
PMID:37364641 PMID:37839492 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
decreases expression increases expression |
EXP |
butylbenzyl phthalate results in decreased expression of LHCGR mRNA butylbenzyl phthalate results in increased expression of LHCGR mRNA; butylbenzyl phthalate results in increased expression of LHCGR protein |
CTD |
PMID:15728792 PMID:31319113 |
|
NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Lonrf2 |
LON peptidase N-terminal domain and ring finger 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LONRF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:41,033,125...41,070,551
Ensembl chr 9:41,034,628...41,070,649
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of LPL mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of LPL mRNA |
CTD |
PMID:26820058 PMID:30768133 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrrc4b |
leucine rich repeat containing 4B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LRRC4B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:94,922,034...94,956,309
Ensembl chr 1:94,935,603...94,956,263
|
|
G |
Lss |
lanosterol synthase |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of LSS mRNA |
CTD |
PMID:35739755 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Lynx1 |
Ly6/neurotoxin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LYNX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:106,632,800...106,638,003
Ensembl chr 7:106,632,797...106,638,023
|
|
G |
Map6 |
microtubule-associated protein 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAP6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:153,568,020...153,634,415
Ensembl chr 1:153,568,368...153,634,414
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP ISO |
butylbenzyl phthalate results in increased phosphorylation of MAPK1 protein [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of MAPK1 protein; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:31319113 PMID:35739755 PMID:37364641 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of MAPK14 protein |
CTD |
PMID:37364641 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
EXP ISO |
butylbenzyl phthalate results in increased phosphorylation of MAPK3 protein [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of MAPK3 protein; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:31319113 PMID:35739755 PMID:37364641 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAPT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mark4 |
microtubule affinity regulating kinase 4 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate] affects the expression of MARK4 protein |
CTD |
PMID:38995844 |
|
NCBI chr 1:79,075,353...79,108,882
Ensembl chr 1:79,068,904...79,108,556
|
|
G |
Mc2r |
melanocortin 2 receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of MC2R mRNA |
CTD |
PMID:32518293 |
|
NCBI chr18:62,001,980...62,015,567
Ensembl chr18:62,004,948...62,015,488
|
|
G |
Mir107 |
microRNA 107 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of MIR107 mRNA |
CTD |
PMID:33395283 |
|
NCBI chr 1:232,337,767...232,337,853
Ensembl chr 1:232,337,767...232,337,853
|
|
G |
Mir141 |
microRNA 141 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR141 |
CTD |
PMID:31199487 |
|
NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332
|
|
G |
Mir15b |
microRNA 15b |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of MIR15B mRNA |
CTD |
PMID:31629899 |
|
NCBI chr 2:153,245,200...153,245,297
Ensembl chr 2:153,245,200...153,245,297
|
|
G |
Mir184 |
microRNA 184 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184 mRNA |
CTD |
PMID:31199487 PMID:35762964 |
|
NCBI chr 8:90,343,134...90,343,210
Ensembl chr 8:90,343,134...90,343,210
|
|
G |
Mir19a |
microRNA 19a |
multiple interactions increases expression |
ISO |
MIR19A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR19A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of PTEN protein]; MIR19A mRNA affects the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR19A mRNA affects the reaction [butylbenzyl phthalate results in increased expression of PCNA protein] butylbenzyl phthalate results in increased expression of MIR19A mRNA |
CTD |
PMID:29864457 |
|
NCBI chr15:92,180,912...92,180,993
Ensembl chr15:92,180,912...92,180,993
|
|
G |
Mir19b1 |
microRNA 19b-1 |
multiple interactions increases expression |
ISO |
MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of PTEN protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in increased expression of PCNA protein] butylbenzyl phthalate results in increased expression of MIR19B1 mRNA |
CTD |
PMID:29864457 |
|
NCBI chr15:92,181,214...92,181,300
Ensembl chr15:92,181,214...92,181,300
|
|
G |
Mir34a |
microRNA 34a |
multiple interactions increases expression decreases expression |
ISO |
MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of MYC protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of PCNA protein] MIR34A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of NAMPT protein] butylbenzyl phthalate results in increased expression of MIR34A mRNA butylbenzyl phthalate results in decreased expression of MIR34A mRNA |
CTD |
PMID:30243731 PMID:34520170 |
|
NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103
|
|
G |
Mirlet7a1 |
microRNA let-7a-1 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of MIRLET7A-1 mRNA |
CTD |
PMID:33395283 |
|
NCBI chr17:16,113,766...16,113,859
Ensembl chr17:16,113,768...16,113,867
|
|
G |
Mirlet7b |
microRNA let-7b |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of MIRLET7B mRNA |
CTD |
PMID:33395283 |
|
NCBI chr 7:116,804,186...116,804,270
Ensembl chr 7:116,804,186...116,804,270
|
|
G |
Mirlet7c1 |
microRNA let-7c-1 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of MIRLET7C-1 mRNA |
CTD |
PMID:33395283 |
|
NCBI chr11:16,201,163...16,201,256
Ensembl chr11:16,201,158...16,201,265
|
|
G |
Mirlet7d |
microRNA let-7d |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of MIRLET7D mRNA |
CTD |
PMID:33395283 |
|
NCBI chr17:16,115,893...16,115,990
Ensembl chr17:16,115,893...16,115,990
|
|
G |
Mirlet7f-1 |
microRNA let7f-1 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of MIRLET7F-1 mRNA |
CTD |
PMID:33395283 |
|
NCBI chr17:16,114,130...16,114,226
Ensembl chr17:16,114,130...16,114,226
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MLLT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP14 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp16 |
matrix metallopeptidase 16 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP16 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:31,312,280...31,556,276
Ensembl chr 5:31,312,280...31,548,388
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression |
ISO |
ZEB1 protein affects the reaction [butylbenzyl phthalate results in increased expression of MMP2 protein] |
CTD |
PMID:31212022 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of MMP3 protein butylbenzyl phthalate promotes the reaction [ETS1 protein binds to MMP3 promoter]; butylbenzyl phthalate promotes the reaction [NR1I2 protein binds to MMP3 promoter] |
CTD |
PMID:33965509 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of MMP9 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of MMP9 mRNA] |
CTD |
PMID:31212022 PMID:33316053 PMID:33965509 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Msh2 |
mutS homolog 2 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of MSH2 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of MVD mRNA |
CTD |
PMID:35739755 |
|
NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions increases expression |
ISO |
MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of MYC protein] butylbenzyl phthalate results in increased expression of MYC mRNA; butylbenzyl phthalate results in increased expression of MYC protein |
CTD |
PMID:30243731 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myocd |
myocardin |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of MYOCD mRNA |
CTD |
PMID:26472102 |
|
NCBI chr10:49,833,219...49,928,806
Ensembl chr10:49,836,641...49,927,627
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of NAMPT mRNA; butylbenzyl phthalate results in decreased expression of NAMPT protein MIR34A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of NAMPT protein] |
CTD |
PMID:34520170 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of NCF1 mRNA |
CTD |
PMID:35739755 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncs1 |
neuronal calcium sensor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NCS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:14,523,220...14,568,829
Ensembl chr 3:14,523,220...14,568,829
|
|
G |
Ndrg4 |
NDRG family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NDRG4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:9,351,408...9,387,398
Ensembl chr19:9,351,404...9,386,914
|
|
G |
Nefh |
neurofilament heavy chain |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFL mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nell1 |
neural EGFL like 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NELL1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:99,709,305...100,573,872
Ensembl chr 1:99,709,793...100,573,860
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of NFE2L2 mRNA [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of NFE2L2 mRNA; [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of NFE2L2 mRNA |
CTD |
PMID:27923775 PMID:37021957 PMID:37364641 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfil3 |
nuclear factor, interleukin 3 regulated |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of NFIL3 mRNA |
CTD |
PMID:15728792 |
|
NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858
|
|
G |
Ngfr |
nerve growth factor receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NGFR mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of NR0B1 mRNA |
CTD |
PMID:15728792 PMID:33983380 |
|
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
butylbenzyl phthalate results in increased activity of NR1I2 protein butylbenzyl phthalate binds to and results in increased activity of NR1I2 protein butylbenzyl phthalate binds to and results in increased activity of NR1I2 protein; butylbenzyl phthalate promotes the reaction [NR1I2 protein binds to ETS1 protein]; butylbenzyl phthalate promotes the reaction [NR1I2 protein binds to MMP3 promoter]; butylbenzyl phthalate results in increased localization of and results in increased activity of NR1I2 protein |
CTD |
PMID:27551952 PMID:33049310 PMID:33965509 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
affects binding increases activity |
ISO |
butylbenzyl phthalate binds to NR1I3 protein butylbenzyl phthalate results in increased activity of NR1I3 protein; butylbenzyl phthalate results in increased activity of NR1I3 protein alternative form |
CTD |
PMID:25938866 PMID:27551952 PMID:28927721 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of NR3C1 mRNA |
CTD |
PMID:32518293 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NR3C2 mRNA |
CTD |
PMID:32518293 |
|
NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of NR4A3 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of NRF1 mRNA |
CTD |
PMID:26520405 PMID:27923775 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Nrxn2 |
neurexin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NRXN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:203,726,420...203,842,301
Ensembl chr 1:203,735,753...203,842,297
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of NSDHL mRNA |
CTD |
PMID:19560483 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Nsg1 |
neuronal vesicle trafficking associated 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:72,648,771...72,670,521
Ensembl chr14:72,648,741...72,670,514
|
|
G |
Nsg2 |
neuronal vesicle trafficking associated 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:15,601,594...15,661,441
Ensembl chr10:15,601,596...15,661,441
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of OCLN protein |
CTD |
PMID:37364641 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Olfm1 |
olfactomedin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of OLFM1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:11,520,522...11,558,240
Ensembl chr 3:11,520,729...11,558,239
|
|
G |
Oxt |
oxytocin/neurophysin I prepropeptide |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of OXT mRNA |
CTD |
PMID:32518293 |
|
NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490
|
|
G |
Oxtr |
oxytocin receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate co-treated with bis(2-propylheptyl)phthalate co-treated with bisphenol A co-treated with 3,5,6-trichloro-2-pyridinol co-treated with 3-phenoxybenzoic acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of OXTR mRNA |
CTD |
PMID:32518293 |
|
NCBI chr 4:145,598,549...145,614,674
Ensembl chr 4:145,599,561...145,614,674
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of PCK1 mRNA |
CTD |
PMID:35739755 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions increases expression |
ISO |
MIR19A mRNA affects the reaction [butylbenzyl phthalate results in increased expression of PCNA protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in increased expression of PCNA protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of PCNA protein] butylbenzyl phthalate results in increased expression of PCNA mRNA; butylbenzyl phthalate results in increased expression of PCNA protein |
CTD |
PMID:29864457 PMID:30243731 PMID:31016752 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pcp4 |
Purkinje cell protein 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PCP4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:35,759,711...35,861,725
Ensembl chr11:35,800,713...35,861,725
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of PCSK9 protein |
CTD |
PMID:38954831 |
|
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in increased secretion of PDGFB protein |
CTD |
PMID:38954831 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdk3 |
pyruvate dehydrogenase kinase 3 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of PDK3 mRNA |
CTD |
PMID:37364641 |
|
NCBI chr X:58,486,699...58,553,533
Ensembl chr X:58,486,554...58,553,557
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of PDK4 protein [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of PDK4 mRNA butylbenzyl phthalate results in increased expression of and results in increased stability of PDK4 mRNA |
CTD |
PMID:31629899 PMID:37364641 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pdp2 |
pyruvate dehydrogenase phosphatase catalytic subunit 2 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of PDP2 mRNA |
CTD |
PMID:31629899 |
|
NCBI chr19:386,408...394,068
Ensembl chr19:386,406...394,074
|
|
G |
Pfkp |
phosphofructokinase, platelet |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of PFKP mRNA |
CTD |
PMID:37364641 |
|
NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Pgam1 |
phosphoglycerate mutase 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of PGAM1 mRNA |
CTD |
PMID:37364641 |
|
NCBI chr 1:240,723,832...240,731,443
Ensembl chr 1:240,723,920...240,738,452
|
|
G |
Pgr |
progesterone receptor |
increases expression multiple interactions |
EXP ISO |
butylbenzyl phthalate results in increased expression of PGR mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PGR mRNA] |
CTD |
PMID:11474214 PMID:33316053 PMID:35307500 PMID:37552060 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of PIK3R1 protein; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased expression of PIK3R1 protein |
CTD |
PMID:35739755 PMID:37364641 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PLAT mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of PLAU protein |
CTD |
PMID:33965509 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plin1 |
perilipin 1 |
multiple interactions increases expression |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PLIN1 protein; [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of PLIN1 mRNA butylbenzyl phthalate results in increased expression of PLIN1 protein |
CTD |
PMID:26820058 PMID:34520170 PMID:37021957 |
|
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Plppr3 |
phospholipid phosphatase related 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLPPR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:9,831,162...9,842,434
Ensembl chr 7:9,831,162...9,845,296
|
|
G |
Pls1 |
plastin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:96,316,703...96,426,592
Ensembl chr 8:96,317,849...96,385,195
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects binding multiple interactions |
ISO |
butylbenzyl phthalate binds to PPARA protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPARA mRNA |
CTD |
PMID:23843199 PMID:28013214 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
affects binding |
ISO |
butylbenzyl phthalate binds to PPARB protein |
CTD |
PMID:23843199 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding increases activity increases expression multiple interactions |
ISO |
butylbenzyl phthalate binds to PPARG protein butylbenzyl phthalate results in increased activity of PPARG protein butylbenzyl phthalate results in increased expression of PPARG mRNA [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PPARG mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PPARG protein; butylbenzyl phthalate binds to and results in increased activity of PPARG protein; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]]; PPARG protein promotes the reaction [butylbenzyl phthalate binds to and results in increased activity of PPARG protein] butylbenzyl phthalate binds to and results in increased activity of PPARG protein; butylbenzyl phthalate inhibits the reaction [GW 1929 binds to PPARG protein] |
CTD |
PMID:23843199 PMID:24155963 PMID:26172262 PMID:26820058 PMID:27923775 PMID:28595985 PMID:31016361 PMID:32407875 PMID:33049310 PMID:34520170 More...
|
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression multiple interactions affects expression |
ISO |
butylbenzyl phthalate results in decreased expression of PPARGC1A mRNA [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of PPARGC1A mRNA butylbenzyl phthalate affects the expression of PPARGC1A mRNA |
CTD |
PMID:26520405 PMID:27923775 PMID:37021957 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPP2R2B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:34,653,716...35,080,889
Ensembl chr18:34,653,721...35,081,025
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRIMA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921
|
|
G |
Prkd1 |
protein kinase D1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate] affects the expression of PRKD1 protein |
CTD |
PMID:38995844 |
|
NCBI chr 6:67,725,193...68,039,002
Ensembl chr 6:67,725,905...68,039,042
|
|
G |
Prpf8 |
pre-mRNA processing factor 8 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate] affects the expression of PRPF8 protein |
CTD |
PMID:38995844 |
|
NCBI chr10:60,331,494...60,354,606
Ensembl chr10:60,331,494...60,354,606
|
|
G |
Prph |
peripherin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRPH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:130,218,149...130,222,136
Ensembl chr 7:130,218,357...130,222,136
|
|
G |
Pten |
phosphatase and tensin homolog |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of PTEN mRNA; butylbenzyl phthalate results in decreased expression of PTEN protein MIR19A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of PTEN protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of PTEN protein] |
CTD |
PMID:29864457 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptger1 |
prostaglandin E receptor 1 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of PTGER1 mRNA |
CTD |
PMID:36746855 |
|
NCBI chr19:24,470,258...24,473,687
Ensembl chr19:24,467,532...24,473,559
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGES mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in decreased expression of PTK2 protein |
CTD |
PMID:37364641 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Ptprn |
protein tyrosine phosphatase, receptor type, N |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTPRN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:76,741,010...76,756,704
Ensembl chr 9:76,741,016...76,756,190
|
|
G |
Ptx3 |
pentraxin 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PTX3 mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of PTX3 protein |
CTD |
PMID:37552060 PMID:38954831 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Qsox1 |
quiescin sulfhydryl oxidase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of QSOX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:67,949,780...67,987,434
Ensembl chr13:67,949,780...67,987,459
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB3B mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB3B protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401
|
|
G |
Rab6b |
RAB6B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB6B mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB6B protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr 8:103,695,328...103,764,023
Ensembl chr 8:103,695,631...103,805,732
|
|
G |
Rarres2 |
retinoic acid receptor responder 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of RARRES2 protein |
CTD |
PMID:38954831 |
|
NCBI chr 4:77,522,549...77,525,733
Ensembl chr 4:77,522,535...77,525,556
|
|
G |
Rassf4 |
Ras association domain family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RASSF4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:149,897,525...149,932,658
Ensembl chr 4:149,897,543...149,932,411
|
|
G |
Rbp4 |
retinol binding protein 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of RBP4 protein |
CTD |
PMID:38954831 |
|
NCBI chr 1:235,893,917...235,901,315
Ensembl chr 1:235,893,917...235,901,399
|
|
G |
Resp18 |
regulated endocrine-specific protein 18 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RESP18 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:76,765,179...76,771,824
Ensembl chr 9:76,764,590...76,778,722
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of RGS2 mRNA] |
CTD |
PMID:37552060 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Rnf183 |
ring finger protein 183 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of RNF183 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:75,877,111...75,886,253
Ensembl chr 5:75,876,003...75,886,191
|
|
G |
Rnps1 |
RNA binding protein with serine rich domain 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate] affects the expression of RNPS1 protein |
CTD |
PMID:38995844 |
|
NCBI chr10:13,445,516...13,455,858
Ensembl chr10:13,445,653...13,455,858
|
|
G |
Rtn1 |
reticulon 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:90,763,212...90,983,436
Ensembl chr 6:90,763,216...90,983,436
|
|
G |
Rtn4r |
reticulon 4 receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN4R mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:82,844,309...82,869,251
Ensembl chr11:82,844,309...82,869,466
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding |
ISO |
butylbenzyl phthalate binds to RXRA protein |
CTD |
PMID:23843199 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Rxrb |
retinoid X receptor beta |
affects binding |
ISO |
butylbenzyl phthalate binds to RXRB protein |
CTD |
PMID:23843199 |
|
NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773
|
|
G |
Rxrg |
retinoid X receptor gamma |
affects binding |
ISO |
butylbenzyl phthalate binds to RXRG protein |
CTD |
PMID:23843199 |
|
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
decreases expression multiple interactions |
EXP ISO |
butylbenzyl phthalate results in decreased expression of SCARB1 mRNA; butylbenzyl phthalate results in decreased expression of SCARB1 protein [dimethyl phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate] results in increased expression of SCARB1 mRNA |
CTD |
PMID:26472102 PMID:31319113 PMID:33983380 PMID:35739735 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of SCD1 mRNA |
CTD |
PMID:35739755 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Scd3 |
stearoyl-coenzyme A desaturase 3 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of SCD3 mRNA |
CTD |
PMID:36756972 |
|
NCBI chr 1:243,093,057...243,114,451
Ensembl chr 1:243,078,774...243,114,229
|
|
G |
Scg3 |
secretogranin III |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCG3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:76,399,777...76,442,015
Ensembl chr 8:76,399,777...76,442,015
|
|
G |
Scn3b |
sodium voltage-gated channel beta subunit 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCN3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:40,630,372...40,652,869
Ensembl chr 8:40,630,455...40,652,868
|
|
G |
Scrn1 |
secernin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCRN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:83,632,125...83,694,225
Ensembl chr 4:83,632,131...83,693,852
|
|
G |
Serpinb2 |
serpin family B member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINB2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Serpinf1 |
serpin family F member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of SERPINF1 protein |
CTD |
PMID:38954831 |
|
NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646
|
|
G |
Sf3b1 |
splicing factor 3b, subunit 1 |
multiple interactions |
ISO |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate] affects the expression of SF3B1 protein |
CTD |
PMID:38995844 |
|
NCBI chr 9:56,492,403...56,532,300
Ensembl chr 9:56,492,403...56,532,300
|
|
G |
Sh3gl3 |
SH3 domain containing GRB2 like 3, endophilin A3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3GL3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:136,124,500...136,255,669
Ensembl chr 1:136,124,499...136,255,584
|
|
G |
Sh3tc2 |
SH3 domain and tetratricopeptide repeats 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3TC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:55,416,383...55,477,419
Ensembl chr18:55,416,413...55,483,083
|
|